About Vida Ventures
Vida Ventures is a venture capital firm founded in 2017. It is primarily based out of Boston, United States. As of Oct 2026, Vida Ventures is an active investor, having invested in 48 companies, with 4 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series B round of Souffle Therapeutics Overall, Vida Ventures portfolio has seen 10 IPOs and 14 acquisitions including key companies like Attovia, AskBio and Aktis Oncology. A lot of funds co-invest with Vida Ventures, with names like Orbimed sharing a substantial percentage of its portfolio. Vida Ventures has team of 24 people including 6 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 7 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Vida Ventures' List of Top Investments
Vida Ventures has a portfolio of 48 companies. Their most notable investments are in Locana and Affini-T Therapeutics.Their portfolio spans across United States, India, China and 3 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 4 other sectors, across stages such as Series A, Series B and 7 more. Here is the list of top investments by Vida Ventures:
Provider of clinical research, development, and commercialization services for life sciences. It offers biomarker-driven research and development, plus commercialization services from product launch through maturity. Services span clinical development, specialty labs, commercial consulting, market access, and medical communications. The organization integrates expertise in lab sciences, translational informatics, regulatory affairs, payer insights, and marketing communications.
Key facts about Precision Medicine Group
- Founded Year: 2012
- Location: Bethesda (United States)
- Valuation: $*****
- Stage: Late Stage
- Total Funding till date: $532M
- Employee Count: 3,675 as on Sep 30, 2026
- Investors: Oak HC/FT, Oak Investment Partners and 8 Others
- Latest Funding Round: PE, Nov 20, 2020, $*****
- Highlight: Editors' Pick
2. Attovia
Developer of antibody-based therapeutics for immune-mediated diseases and oncology. The company leverages ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. It develops a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology.
Key facts about Attovia
- Founded Year: 2023
- Location: Fremont (United States)
- Stage: Public
- Total Funding till date: $255M
- Employee Count: 54 as on Sep 30, 2026
- Investors: Marshall Wace, Frazier Life Sciences and 13 Others
- Latest Funding Round: Series C, Apr 15, 2025, $*****
- Highlight: Public
3. AskBio
Developer of AAV technologies for treating genetic and complex disorders. The company is engaged in the development and delivery of novel protein and cellular-based therapies through the design of proprietary recombinant Adeno associated virus (AAV) Biological Nano Particles (BNP). The gene delivery technology platform provides unsurpassed transduction efficiency, "ramp-up" expression capabilities, with tissue targeting and de-targeting properties. Its product pipeline includes drugs to treat muscular dystrophy, hemophilia B, congestive heart failure, epilepsy, retinitis pigmentosa, and osteoporosis.
Key facts about AskBio
- Founded Year: 2001
- Location: Durham (United States)
- Stage: Acquired
- Total Funding till date: $235M
- Employee Count: 511 as on Sep 30, 2026
- Investors: Columbus Venture Partners, Vida Ventures and 4 Others
- Latest Funding Round: Grant (prize money), Sep 02, 2020, $*****
- Highlight: Acquired
Developer of radiopharmaceuticals for solid tumor cancers. The company had developed platforms to generate tumor-targeting agents for radiotherapy that are designed for high tumor penetration and long residence time. The therapeutic radioisotope molecules developed eliminates tumors from the body and minimize the side effects.
Key facts about Aktis Oncology
- Founded Year: 2021
- Location: Boston (United States)
- Stage: Public
- Total Funding till date: $336M
- Employee Count: 107 as on Sep 30, 2026
- Investors: RTW Investments, ArrowMark Partners and 16 Others
- Latest Funding Round: Series B, Sep 20, 2024, $*****
- Highlight: Public
Dyne Therapeutics provides nucleic acid therapies for rare diseases. The company offers proprietary technology for muscles disorder, myotonic dystrophy, and others. The company also offers treatments for rare genetic diseases, drug discovery and development, linker chemistry, antibiotics engineering, and others.
Key facts about Dyne Therapeutics
- Founded Year: 2017
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $166M
- Employee Count: 323 as on Sep 30, 2026
- Investors: Atlas Venture, Logos and 5 Others
- Latest Funding Round: Series B, Aug 10, 2020, $*****
- Highlight: Public
Vida Ventures' Year-on-Year Investment Trends
Vida Ventures has invested in 48 companies over the last 9 years, with an average of 3 new investments annually in the last 5 years. In 2025, it made 4 investments, while as of Oct 2026, it has made 6 investments in this year. Its most recent first time investment was in SonoThera and most recent follow-on round was in Souffle Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 3 | 3 | 6 |
2025 | 4 | 0 | 4 |
2024 | 4 | 2 | 6 |
2023 | 1 | 4 | 5 |
2022 | 1 | 5 | 6 |
2021 | 9 | 2 | 11 |
2020 | 10 | 4 | 14 |
2019 | 8 | 1 | 9 |
2018 | 3 | 0 | 3 |
2017 | 4 | 0 | 4 |
Vida Ventures' Investments by Stage
Vida Ventures has made 16 investments in Series A stage with an average round size of $120M, 10 investments in Series B stage with an average round size of $100M and 7 investments in Seed stage with an average round size of $16.2M.Stage of entry | No. of Investments |
|---|---|
Series A | 16 |
Series B | 10 |
Seed | 7 |
Series C | 6 |
PE | 2 |
Others | 6 |
Note: We have considered here, only first round of investments
Vida Ventures' Investments by Sector
Vida Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Consumer and Enterprise Applications. Notably, it has invested in 43 Enterprise (B2B) companies, 43 Tech companies, 4 Consumer (B2C) companies and at least 3 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 42 |
High Tech | 6 |
HealthTech | 2 |
Consumer | 1 |
Enterprise Applications | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
Vida Ventures' Investments by Geography
Vida Ventures has made most investments in United States (40), followed by India where it has made 3 investments.Country | No. of Investments |
|---|---|
United States | 40 |
India | 3 |
China | 1 |
Denmark | 1 |
France | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Vida Ventures' recent investments
Vida Ventures has made 6 investments in 2026 so far. Souffle Therapeutics and InduPro are the latest among them.Here are the most recent investments by Vida Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 13, 2026 | United States | Series B | 8546 | [+15] | |
Aug 12, 2026 | United States | Series B | 1187 | [+6] | |
Jun 08, 2026 | United States | Series B | 5399 | ||
Apr 14, 2026 | Denmark | Series C | 8302 | [+15] | |
Mar 03, 2026 | United States | Series A | 5826 |
IPOs and Publicly Listed companies in Vida Ventures' Portfolio
10 of Vida Ventures' portfolio companies have become public. Attovia got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Aug 2026 at marketcap of $731M and Avalyn Pharma got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $753M.Here are Vida Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 05, 2026 | Apr 15, 2025 | Series C | 6736 | |
Apr 30, 2026 | Sep 27, 2023 | Series C | 2878 | |
Jan 09, 2026 | Mar 18, 2021 | Series A | 1370 | |
Feb 08, 2024 | Jan 13, 2020 | Series A | 4140 | |
Nov 01, 2021 | Oct 29, 2020 | Unattributed | 7669 |
Acquired companies in Vida Ventures' Portfolio
14 companies from Vida Ventures' portfolio have been acquired. The most recent acquisition was Candid Therapeutics in May 2026 by UCB for $*****.Here are Vida Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 03, 2026 | Sep 09, 2024 | Series D | 5687 | |
Mar 31, 2026 | Feb 16, 2021 | Series A | 4643 | |
Nov 17, 2025 | Aug 12, 2024 | Series B | 5300 | |
Jul 01, 2025 | Nov 24, 2021 | Seed | 3929 | |
May 21, 2025 | Aug 18, 2021 | Series B | 2667 |
Team profile of Vida Ventures
Vida Ventures has a team of 24 members including 6 Partners and 3 Principals located in United States. Vida Ventures' team does not sit on the board of any company as of now.Here is a list of top team members in Vida Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Los Angeles | - | - | |
Partner | Boston | - | - | |
Partner | - | - | - | |
Partner | Boston | - | - | |
Partner | Santa Monica | - | - | |
Partner | San Francisco | - | - | |
Principal | Boston | - | - | |
Principal | Boston | - | - | |
Principal | Los Angeles | - | - |
Co-investors of Vida Ventures
Over the past 9 years, 463 investors have co-invested in Vida Ventures's portfolio companies. This includes funds and angels.
- Invested before Vida Ventures: HHS, Arch Venture Partners and 96 others have invested in rounds before Vida Ventures. There are 4 companies where HHS has invested before Vida Ventures and 4 companies where Arch Venture Partners has invested before Vida Ventures.
- Top Co-investors of Vida Ventures: 229 investors entered a company along with Vida Ventures. These include investors like Orbimed (8 companies).
- Invested after Vida Ventures: A total of 136 investors have invested in Vida Ventures's portfolio after their investments. Top Investors include Janus Henderson Investors (6 companies), Fidelity Investments (5 companies) and Citadel (5 companies).
Recent News related to Vida Ventures
•
InduPro Announces $77 Million Series B Financing and Dosing of First Patient in Phase 1 Oncology Studytimesargus.com•Aug 12, 2026•InduPro, Lilly, The Column Group, Sanofi and 5 others
•
SonoThera raises $125M for non-viral gene therapy approachEndpoints•Jun 10, 2026•SonoThera, Medical Excellence Capital, UCB Ventures, Leaps by Bayer and 10 others
•
Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCBBusiness Wire•May 04, 2026•Vida Ventures, Two River
•
Adcendo ApS Completes $75 Million Series C FinancingCNW•Apr 14, 2026•Jeito, Bpifrance, Danmarks Eksport og Investeringsfond, Adcendo and 12 others
•
Poplar Therapeutics Closes $45 million Series A Extension to Advance Development of Lead Program, PHB-050, A New Class of Anti-IgE Therapy for Multiple Atopic ConditionsBusiness Wire•Mar 03, 2026•Poplar Therapeutics, Vida Ventures, RA Capital Management, Janus Henderson Investors and 4 others
•
Poplar Therapeutics Secures $50M Series A for Anti-IgE Therapy DevelopmentPulse 2.0•Jan 09, 2026•Vida Ventures, SR One, ALDEN POPLAR CREEK REHAB AND HEALTH CARE CENTER, INC., Poplar Therapeutics and 2 others
•
•
Protego gets $130M for AL amyloidosis drug from leaders behind VyndaqelEndpoints•Dec 01, 2025•Protegobio, Brown Rudnick, Omega Funds, Novartis Venture Fund and 8 others
•
Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven StrategyBusiness Wire•Nov 18, 2025•Vida Ventures
•
The Endpoints 11: Third Arc raises $198.5M to tackle major disease targetsEndpoints•Sep 19, 2025•Third Arc Bio, Vida Ventures
